AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Study ID: STU 102014-066

Summary

Participant Eligibility

Cancer Related

Yes

Healthy Volunteers

No

UT Southwestern Principal Investigator

Tamra Lynn Slone

CHILDRENS ONCOLOGY GROUP OPERATIONS CTR

414361f6-e401-4323-9609-82e5a2dd6bc6